Skip to main content

Main menu

  • HOME
  • LATEST ARTICLES
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • RESOURCES
    • About BJGP Open
    • BJGP Open Accessibility Statement
    • Editorial Board
    • Editorial Fellowships
    • Audio Abstracts
    • eLetters
    • Alerts
    • Outreach
    • Feedback
    • BJGP Life
    • Advertising
    • Research into Publication Science
    • Conference
  • SPECIAL ISSUES
    • Special issue: Telehealth
    • Special issue: Race and Racism in Primary Care
    • Special issue: COVID-19 and Primary Care
    • Past research calls
  • RCGP
    • British Journal of General Practice
    • BJGP for RCGP members
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers

User menu

  • Alerts

Search

  • Advanced search
Intended for Healthcare Professionals
BJGP Open
  • RCGP
    • British Journal of General Practice
    • BJGP for RCGP members
    • RCGP eLearning
    • InnovAIT Journal
    • Jobs and careers
  • Subscriptions
  • Alerts
  • Log in
  • Follow bjgp on Twitter
  • Visit bjgp on Facebook
  • Blog
Intended for Healthcare Professionals
BJGP Open

Advanced Search

  • HOME
  • LATEST ARTICLES
  • ALL ISSUES
  • AUTHORS & REVIEWERS
  • RESOURCES
    • About BJGP Open
    • BJGP Open Accessibility Statement
    • Editorial Board
    • Editorial Fellowships
    • Audio Abstracts
    • eLetters
    • Alerts
    • Outreach
    • Feedback
    • BJGP Life
    • Advertising
    • Research into Publication Science
    • Conference
  • SPECIAL ISSUES
    • Special issue: Telehealth
    • Special issue: Race and Racism in Primary Care
    • Special issue: COVID-19 and Primary Care
    • Past research calls
Practice & Policy

Supporting patients with long-term problems after Lyme disease

Victoria Cairns
BJGP Open 2020; 4 (3): bjgpopen20X101102. DOI: https://doi.org/10.3399/bjgpopen20X101102
Victoria Cairns
1 Consultant Statistician, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: v.cairns@outlook.com
  • Article
  • Info
  • eLetters
  • PDF
Loading
  • Post treatment Lyme disease syndrome
  • Post-Lyme Disease Syndrome
  • Lyme disease
  • General practice
  • Primary health care

There has been controversy about Lyme disease (LD), first about whether people really can have persistent problems after Lyme disease, and then about whether more antibiotic treatment is beneficial if they do still have symptoms. This overview compiles into one summary information about what the studies have found about the cause of the symptoms and the possible treatments, so that GPs are better able to advise patients who have the long-term problems.

Some patients have persistent symptoms after LD, despite having had the recommended antibiotic treatment. A small proportion of LD patients have a relevant delay in treatment, which may increase their risk for the development of problems that can last a long time, perhaps a few years. These delays can sometimes result from the difficulty of diagnosis, particularly as many LD cases do not have the erythema migrans rash.1 Catching LD while holidaying abroad may make a delay more likely because it may be some time before the patient returns home and sees a doctor. The Royal College of General Practitioners has prepared an LD toolkit2 and mentions post-treatment Lyme disease syndrome (PTLDS) as one term used to describe these long-term problems. PTLDS can significantly impact quality of life3 and recovery may be extremely slow, with no apparent improvement from one month to the next, although very subtle improvement may be seen from one year to the next.

PTLDS results in extreme fatigue, cognitive disorders, and musculoskeletal pain. The fatigue has been described as profound and debilitating. The musculoskeletal pain is often roving, asymmetrical pain in the limbs, and is unlike fibromyalgia.4 Memory problems, particularly verbal memory, are also observed, as well as poor concentration, including auditory attention. A study by Fallon et al has shown that patients with PTLDS demonstrated significant flow reductions in white matter areas in the brain, and that the flow reductions were significantly associated with deficits in memory and visuospatial organisation.5 There is some symptom overlap with chronic fatigue syndrome (CFS), but the symptoms of PTLDS, including fatigue, can be clinically significant and long-lasting,3 whereas a key symptom of CFS is reported to be post-exertional malaise lasting more than 24 hours,6 and there are other differences. A review by Uhde et al pointed out that there is evidence of inflammation from the marker C-reactive protein seen with PTLDS, but not with CFS.7

Sometimes, after eradication of the actively dividing LD spirochete, there may be debris remaining which can explain some of the long-term symptoms. A study by Jutras et al identified a chemically typical peptidoglycan as a likely contributor to inflammatory responses in Lyme arthritis. Persistence of this antigen in the joint may contribute to synovitis after antibiotics eradicate the pathogen.8 A study by Parthasarathy et al showed that non-viable LD bacteria (heat-killed or sonicated bacteria) induced inflammation and apoptosis of human oligodendrocytes, and they concluded that residues left after bacterial demise may continue to be pathogenic to the central nervous system.9 The expression chronic LD may be misunderstood, and some people may mistakenly think they have ongoing spirochetal infection requiring extensive antibiotic treatment, while their symptoms may be from the debris of morphological forms of LD bacteria that are resistant to antibacterial therapy, and those patients may be endangering their health by taking prolonged courses of antibiotics that can lead to other infections.10

In a study of autopsy tissues from a patient who had died after many years of antibiotic treatment for LD, Sapi et al found evidence indicating that the LD bacteria Borrelia burgdorferi can persist in the human body in the antibiotic-resistant biofilm form, even after long-term antibiotic treatment. They found evidence in many parts of her body and the presence of infiltrating lymphocytes in the vicinity of Borrelia burgdorferi biofilms, which suggests that the organism in biofilm form might trigger chronic inflammation.11 They wrote that Borrelia antigens and DNA are associated with biofilms, and that one hypothesis for their persistence is that different morphological forms of Borrelia may protect the bacteria from antibacterial therapy.

Since antibiotics do not appear to be effective against these forms of Borrelia, other kinds of treatment are needed. Socarras et al did an in vitro study on the antimicrobial activity of bee venom and its component melittin against Borrelia burgdorferi persisters, and their findings showed that bee venom melittin had significant effects on all the tested forms of Borrelia burgdorferi.12 Feng et al have tested various botanical and natural products, and found several to be highly active in vitro against what they called stationary phase Borrelia burgdorferi. The authors concluded that future studies should be directed at identifying the active constituents of each botanical, evaluating synergistic combinations, and confirming their safety and efficacy.13

Continuing with antibiotic treatment may affect the immune system in a variety of other ways. Bernardino et al did a study on monkey brain cells stimulated with LD bacteria and showed that doxycycline moderated the inflammatory response.14 They concluded that, in people with PTLDS who experience a beneficial effect from retreatment with doxycycline, this effect may be due to the anti-inflammatory properties of the antibiotic.

A review by Balducci et al highlights that the antibiotic tetracyclines, besides having antimicrobial activity, also have pleiotropic action against amyloidosis, neuroinflammation, and oxidative stress.15

A study by Fallon et al found that some of the PTLDS patients in their trial experienced moderate short-term cognitive improvement from ceftriaxone treatment.16

Tai et al have reviewed studies of ceftriaxone which demonstrated that ceftriaxone can have the effect of increasing glutamate transporter-1 expression and glutamate reuptake, thereby suppressing excitotoxicity, and that it also enhances neurogenesis and recovery of neuronal density.17 Since ceftriaxone has been shown to have these effects, it is not surprising that some patients with PTLDS may have had some slight improvement in their levels of fatigue and their cognition deficits after a repeated course of ceftriaxone.

The challenge can be in determining whether previous antibiotic treatment has effectively killed the actively dividing LD spirochete, as direct tests are not always accurate or available to clinicians. The oral antibiotic doxycycline is usually effective for early LD, leaving the patient with no further problems, but oral antibiotics may not be effective if the infection has reached the later stages of the disease, when intravenous ceftriaxone may be recommended. Some specialists have said that if the patient is getting better, however slowly, then this is a sign that no further antibiotic treatment is needed.

In many patients with persistent symptoms, the symptoms fade away very slowly over time, and so it appears that there is some gradual recovery taking place, which may be neurological recovery, eventual breakdown of the debris, or a slow cessation of the chronic inflammation.

There are insufficient studies from which to draw definitive conclusions regarding the efficacy of repeated antibiotic therapy. For many patients, further treatment does not appear to provide much benefit, but it may be appropriate for those patients where it is thought that the actively dividing LD spirochete might not have been eradicated; that is a difficult judgement, however.

Instead of receiving repeated antibiotics, which bring some risk and appear to provide little benefit to patients with PTLDS, there are some food supplements that may help to some extent with recovery.

Natural products are sometimes good as therapeutic agents, particularly given their minimal side effects. Manuka honey has been found to have various biological properties, including antioxidant and antimicrobial capacities.18 It can react with macromolecules such as DNA, RNA and proteins, without any damage to host cells. Omega-3 fatty acids that are found in natural fish oil have been shown to help with minor cognitive impairment,19 and vitamin B12 has been shown to be beneficial in nerve regeneration.20 The spice turmeric, also known as curcumin, may help reduce joint inflammation,21 and Sirtuin 3 has been identified as a key regulator of mitochondrial fission, and it may help reduce neuroinflammation.22 The Sirtuin enzymes are activated by foods like green tea, dark chocolate, and blueberries.

The regrowth of neural pathways is, however, extremely slow, and recovery will inevitably take a long time, with or without any such supplements. The potential harm from inappropriate doses of alternative therapies also needs to be recognised. Nevertheless, patients may feel encouraged if they hear of anything that they can do which may help their recovery, even if only a little. It has not been shown whether any of the above products could help with the long-term recovery from PTLDS, but the main message for those suffering from persistent problems after having had the recommended antibiotic treatment is that PTLDS is recognised, and that many people do recover with time.

Notes

Funding

No funding was received for this article.

Ethical approval

No ethical approval was required for this article.

Provenance

Freely submitted; externally peer reviewed.

Competing interests

The authors declare that no competing interests exist.

  • Received March 17, 2020.
  • Accepted April 22, 2020.
  • Copyright © 2020, The Authors

This article is Open Access: CC BY license (https://creativecommons.org/licenses/by/4.0/)

References

  1. 1.↵
    1. Cairns V
    (2020) Lyme disease: implications for general practice. Br J Gen Pract 70(692):106–107, doi:10.3399/bjgp20X708341, pmid:http://www.ncbi.nlm.nih.gov/pubmed/32107217.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Royal College of General Practitioners
    RCGP Lyme disease toolkit. 5 Jun 2020. https://www.rcgp.org.uk/clinical-and-research/resources/toolkits/lyme-disease-toolkit.aspx.
  3. 3.↵
    1. Rebman AW,
    2. Bechtold KT,
    3. Yang T,
    4. et al.
    (2017) The clinical, symptom, and quality-of-life characterization of a well-defined group of patients with posttreatment Lyme disease syndrome. Front Med (Lausanne) 4(224):224, doi:10.3389/fmed.2017.00224, pmid:29312942.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Cairns V,
    2. Godwin J
    (2005) Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol 34(6):1340–1345, doi:10.1093/ije/dyi129, pmid:http://www.ncbi.nlm.nih.gov/pubmed/16040645.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Fallon BA,
    2. Keilp J,
    3. Prohovnik I,
    4. et al.
    (2003) Regional cerebral blood flow and cognitive deficits in chronic Lyme disease. J Neuropsychiatry Clin Neurosci 15(3):326–332, doi:10.1176/jnp.15.3.326, pmid:http://www.ncbi.nlm.nih.gov/pubmed/12928508.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Cortes Rivera M,
    2. Mastronardi C,
    3. Silva-Aldana CT,
    4. et al.
    (2019) Myalgic Encephalomyelitis/Chronic fatigue syndrome: a comprehensive review. Diagnostics 9(3):91, doi:10.3390/diagnostics9030091, pmid:http://www.ncbi.nlm.nih.gov/pubmed/31394725.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Uhde M,
    2. Indart A,
    3. Fallon BA,
    4. et al.
    (2018) C-reactive protein response in patients with post-treatment Lyme disease symptoms versus those with myalgic encephalomyelitis/chronic fatigue syndrome. Clin Infect Dis 67(8):1309–1310, doi:10.1093/cid/ciy299, pmid:http://www.ncbi.nlm.nih.gov/pubmed/29741589.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Jutras BL,
    2. Lochhead RB,
    3. Kloos ZA,
    4. et al.
    (2019) Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis. Proc Natl Acad Sci U S A 116(27):13498–13507, doi:10.1073/pnas.1904170116, pmid:http://www.ncbi.nlm.nih.gov/pubmed/31209025.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Parthasarathy G,
    2. Fevrier HB,
    3. Philipp MT
    (2013) Non-Viable Borrelia burgdorferi induce inflammatory mediators and apoptosis in human oligodendrocytes. Neurosci Lett 556:200–203, doi:10.1016/j.neulet.2013.10.032, pmid:http://www.ncbi.nlm.nih.gov/pubmed/24157855.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Shelton A,
    2. Giurgea L,
    3. Moshgriz M,
    4. et al.
    (2019) A case of Mycobacterium goodii infection related to an indwelling catheter placed for the treatment of chronic symptoms attributed to Lyme disease. Infect Dis Rep 11(2), doi:10.4081/idr.2019.8108, pmid:http://www.ncbi.nlm.nih.gov/pubmed/31579470. 8108.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Sapi E,
    2. Kasliwala RS,
    3. Ismail H,
    4. et al.
    (2019) The Long-Term Persistence of Borrelia burgdorferi Antigens and DNA in the Tissues of a Patient with Lyme Disease. Antibiotics 8(4):183, doi:10.3390/antibiotics8040183, pmid:http://www.ncbi.nlm.nih.gov/pubmed/31614557.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Socarras KM,
    2. Theophilus PAS,
    3. Torres JP,
    4. et al.
    (2017) Antimicrobial activity of bee venom and melittin against Borrelia burgdorferi. Antibiotics 6(4):31, doi:10.3390/antibiotics6040031, pmid:http://www.ncbi.nlm.nih.gov/pubmed/29186026.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Feng J,
    2. Leone J,
    3. Schweig S,
    4. et al.
    (2020) Evaluation of Natural and Botanical Medicines for Activity Against Growing and Non-growing Forms of B. burgdorferi Front Med (Lausanne) 7(7):6, doi:10.3389/fmed.2020.00006, pmid:32154254.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Bernardino ALF,
    2. Kaushal D,
    3. Philipp MT
    (2009) The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi J Infect Dis 199(9):1379–1388, doi:10.1086/597807, pmid:http://www.ncbi.nlm.nih.gov/pubmed/19301981.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Balducci C,
    2. Forloni G
    (2019) Doxycycline for Alzheimer's disease: fighting β-amyloid oligomers and neuroinflammation. Front Pharmacol 10, doi:10.3389/fphar.2019.00738, pmid:http://www.ncbi.nlm.nih.gov/pubmed/31333460. 738.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Fallon BA,
    2. Keilp JG,
    3. Corbera KM,
    4. et al.
    (2008) A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 70(13):992–1003, doi:10.1212/01.WNL.0000284604.61160.2d, pmid:http://www.ncbi.nlm.nih.gov/pubmed/17928580.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Tai C-H,
    2. Bellesi M,
    3. Chen A-C,
    4. et al.
    (2019) A new avenue for treating neuronal diseases: ceftriaxone, an old antibiotic demonstrating behavioral neuronal effects. Behav Brain Res 364:149–156, doi:10.1016/j.bbr.2019.02.020, pmid:http://www.ncbi.nlm.nih.gov/pubmed/30768995.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Carter DA,
    2. Blair SE,
    3. Cokcetin NN,
    4. et al.
    (2016) Therapeutic manuka honey: no longer so alternative. Front Microbiol 7(265), doi:10.3389/fmicb.2016.00569, pmid:http://www.ncbi.nlm.nih.gov/pubmed/27148246. 569.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Fiala M,
    2. Halder RC,
    3. Sagong B,
    4. et al.
    (2015) ω-3 Supplementation increases amyloid-β phagocytosis and resolvin D1 in patients with minor cognitive impairment. Faseb J 29(7):2681–2689, doi:10.1096/fj.14-264218, pmid:http://www.ncbi.nlm.nih.gov/pubmed/25805829.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Gröber U,
    2. Kisters K,
    3. Schmidt J
    (2013) Neuroenhancement with vitamin B12-underestimated neurological significance. Nutrients 5(12):5031–5045, doi:10.3390/nu5125031, pmid:http://www.ncbi.nlm.nih.gov/pubmed/24352086.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Daily JW,
    2. Yang M,
    3. Park S
    (2016) Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomized clinical trials. J Med Food 19(8):717–729, doi:10.1089/jmf.2016.3705, pmid:27533649.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Zhou D,
    2. Jiang Y
    (2019) Sirtuin 3 attenuates neuroinflammation-induced apoptosis in BV-2 microglia. Aging (Albany NY) 11(20), 9089, doi:10.18632/aging.102375, pmid:31631063. 9075.
    OpenUrlCrossRefPubMed
Back to top
Previous ArticleNext Article

In this issue

BJGP Open
Vol. 4, Issue 3
August 2020
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Or,
sign in or create an account with your email address
Email Article

Thank you for recommending BJGP Open.

NOTE: We only request your email address so that the person to whom you are recommending the page knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Supporting patients with long-term problems after Lyme disease
(Your Name) has forwarded a page to you from BJGP Open
(Your Name) thought you would like to see this page from BJGP Open.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Supporting patients with long-term problems after Lyme disease
Victoria Cairns
BJGP Open 2020; 4 (3): bjgpopen20X101102. DOI: 10.3399/bjgpopen20X101102

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Supporting patients with long-term problems after Lyme disease
Victoria Cairns
BJGP Open 2020; 4 (3): bjgpopen20X101102. DOI: 10.3399/bjgpopen20X101102
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Mendeley logo Mendeley

Jump to section

  • Top
  • Article
    • Notes
    • References
  • Info
  • eLetters
  • PDF

Keywords

  • Post treatment Lyme disease syndrome
  • Post-Lyme Disease Syndrome
  • Lyme disease
  • general practice
  • Primary health care

More in this TOC Section

  • Reconsidering the Levesque framework: a social work perspective for healthcare professionals
  • Environmental impact ratings that could drive positive environmental changes in the manufacture and use of pharmaceuticals
  • An analysis of Public Health England’s vaccination data for care home workers immediately preceding a ‘Roadmap out of COVID-19 Lockdown’
Show more Practice & Policy

Related Articles

Cited By...

Intended for Healthcare Professionals

@BJGPOpen's Likes on Twitter

 
 

British Journal of General Practice

NAVIGATE

  • Home
  • Latest articles
  • Authors & reviewers
  • Accessibility statement

RCGP

  • British Journal of General Practice
  • BJGP for RCGP members
  • RCGP eLearning
  • InnovAiT Journal
  • Jobs and careers

MY ACCOUNT

  • RCGP members' login
  • Terms and conditions

NEWS AND UPDATES

  • About BJGP Open
  • Alerts
  • RSS feeds
  • Facebook
  • Twitter

AUTHORS & REVIEWERS

  • Submit an article
  • Writing for BJGP Open: research
  • Writing for BJGP Open: practice & policy
  • BJGP Open editorial process & policies
  • BJGP Open ethical guidelines
  • Peer review for BJGP Open

CUSTOMER SERVICES

  • Advertising
  • Open access licence

CONTRIBUTE

  • BJGP Life
  • eLetters
  • Feedback

CONTACT US

BJGP Open Journal Office
RCGP
30 Euston Square
London NW1 2FB
Tel: +44 (0)20 3188 7400
Email: bjgpopen@rcgp.org.uk

BJGP Open is an editorially-independent publication of the Royal College of General Practitioners

© 2022 BJGP Open

Online ISSN: 2398-3795